In patients with multiple myeloma receiving polychemotherapy, infectious complication incidence dropped from 22 to 8.3% following immunity correction drugs including thymaline.
In plain wordsIn multiple myeloma patients receiving polychemotherapy, immunity correction drugs including thymaline were linked to fewer infectious complications.
- Peptide
- Thymalin
- Outcome
- DecreaseInfectious complication incidence
- Study
n: not reported in source
- Outcome group
- Infection and antimicrobial activity · Infection
Measurements
- Infectious complication incidence before
- 22%
- group II
- Infectious complication incidence after
- 8.3%
- group II
Source sentences
Following the administration of immunity correction drugs (thymaline, tactivin, immunoglobulin), infectious complication incidence in group II dropped from 22 to 8.3%.
1 context sentence(design, population, supporting numbers)
A retrospective analysis of survival time and causes of death has been undertaken in 109 patients treated for multiple myeloma (MM) at the Hematologic Clinic of the Russian Research Institute of Hematology and Transfusiology in 1979-1995.
In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.